Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

NCT00243568 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

HIV Infections
Acquired Immunodeficiency Syndrome

Interventions

DRUG: Vicriviroc

Sponsor

Merck Sharp & Dohme LLC